Acquired in June 2023, the Lucis acquisition brings accelerated growth opportunities for Rosemont through a broadened portfolio, with access to new attractive product areas and further pipeline products.

Founded in 2012, Lucis is a dedicated provider in the development and licensing of high-quality generic medicines, committed to improving healthcare accessibility and affordability. Our focus is on delivering effective and safe medications that meet rigorous standards.

This acquisition will enable Rosemont to broaden its portfolio and enter the unit dose / sachet market through the pipeline products, whilst growing the business through recent Lucis product launches in 2021/22.

Rosemont enhances its ability to develop products for global market with acquisition of Sabal Therapeutics and its affiliates Metacel Pharmaceuticals, Palmetto Pharmaceuticals, Athena Bioscience and Sarras Health.

Leeds, UK – (July 2024) – Rosemont Pharmaceuticals Ltd. (“Rosemont”), a leading developer, manufacturer, and distributor of liquid medicines for over 50 years, has acquired Sabal Therapeutics and its affiliates Metacel Pharmaceuticals, Palmetto Pharmaceuticals, Athena Bioscience and Sarras Health, a group of privately owned specialty pharmaceutical companies and distributors of prescription, liquid medicines, based in Watkinsville, Georgia, USA.

This acquisition further enhances Rosemont’s ability to serve patients with swallowing difficulties across the USA. Previously, Rosemont has developed, registered and supplied medicines to the US market via distribution partners. This acquisition now provides the company with the ability to supply branded and generic medicines directly into the US market. In addition to the existing portfolio included in this transaction, Rosemont has an extensive pipeline of novel, liquid medicines designed for the US market and patients.

Howard Taylor CEO of Rosemont said“Acquiring Sabal is a key milestone for Rosemont to commercialise our world class medicines to help US patients with swallowing difficulties, building on our platform of high-quality development teams in both the UK and Greece. Our Vice President for the US Market, John Denman, who heads our Rosemont Inc US operations, will be leading this venture and all of us at Rosemont are looking forward to working with the Sabal team.”

Sabal president and CEO Jeff Bryant said, “this fusion of Rosemont and Sabal allows us to greatly expand our vision across therapeutic areas, with the ultimate mission of changing patients’ lives for the better. We are delighted to join the Rosemont team to deliver even greater value to our providers and those in their care.”

For more information, please contact:

Janet Maclean at Janet.Maclean@rosemontpharma.com

About Rosemont Pharmaceutical Ltd.

Rosemont has over 50 years of expertise in the development, manufacture and distribution of oral liquid medicines. Since the release of its first liquid medicine in 1974, Rosemont has continued conducting research, developing and bringing new products to market advocating support for vulnerable patients with swallowing difficulties. As of 2024, Rosemont has a portfolio of over 130 oral liquid medicines across a range of therapeutic areas including over 100 licensed products in 27 international markets.

Learn more at www.rosemontpharma.com

About Sabal Therapeutics

Sabal is a fully integrated pharmaceutical company that has sales and marketing capabilities, with an additional commercial office based in Greenville, South Carolina, to promote its own assets developed by CROs and manufactured by CMOs, commissioned by Sabal. It has the requisite operations, quality, pharmacovigilance and financial management teams, based in Watkinsville, Georgia, and its own 3PL in support of its trade relations and distribution, located in Bogart, Georgia.

Learn more at www.sabaltherapeutics.com

ROS000116, DOP July 2024

Investors in Diversity

Rosemont Pharmaceuticals has successfully achieved the Investors in Diversity Silver Accreditation.

The liquid pharmaceutical specialists based in the UK have been working closely with Investors in Diversity to earn this important standard that sets out a framework for ensuring fairness and a sense of belonging in the workplace.

The organisation sets out a framework (FREDIE) which aims to improve fairness, respect, equality, diversity, inclusion, and engagement within the workplace. A key goal of pursuing this award is to engage employees in the values of Rosemont and recognise that everyone has a voice in the continual improvement of the employee experience. We are delighted with this testament to Rosemont’s passion for creating a diverse and inclusive environment for their employees, that they have been able to achieve this accreditation. Rosemont will continue to be supported by Investors in Diversity on this journey and will be using insights from the FREDIE plan to shape our future plans.

ROS000083, DOP June 2024

Rosemont enhances its ability to develop products for global market with acquisition of Pharma-Data S.A.

Rosemont Pharmaceuticals Ltd. (“Rosemont”), a leading developer, manufacturer and distributor of liquid medicines for over 50 years, has acquired Pharma-Data S.A. (“Pharma-Data”), a privately owned Research and Development Organisation based in Lavrion, Greece.

Pharma-Data specialises in Research & Development (R&D) and development of Value-Added Medicinal Drug Products for Europe and USA and has its own Good Manufacturing Practice (GMP) approved, R&D Galenical and Analytical laboratory in Athens, Greece. The company also provides services in contract development, dossier writing, technology transfer, licensing and regulatory services on a global basis.

This acquisition complements Rosemont’s already extensive product development capability in house as well as improving Rosemont’s capability to develop other dosage forms and modified release oral liquids.

Howard Taylor CEO of Rosemont said “Acquiring and accessing Pharma-Data is both exciting and significant for Rosemont Pharmaceuticals. Firstly, it reinforces our commitment to develop novel, patient-centric medicines for patients who prefer liquid medicines; and secondly, it is Rosemont’s first step towards having international affiliates beyond the United Kingdom. Everyone at Rosemont is looking forward to working with the team in Greece.”

Yannis Psarrakis’s CEO, Pharma-Data said “We are enthusiastic about joining the Rosemont family! We emphatically believe that this acquisition epitomises our endeavours for the provision of high-quality, value-added medicines and will lead to a plethora of synergies, ensuring that both Rosemont and Pharma-Data are always focused on new therapeutic approaches. We are looking forward to this new era and working closely with our new colleagues!”

ROS000100, DOP June 2024